<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426530</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001J2102</org_study_id>
    <secondary_id>2006-001595-20</secondary_id>
    <nct_id>NCT00426530</nct_id>
  </id_info>
  <brief_title>Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at different dose levels and regimens of everolimus combined with weekly
      trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the feasible dose levels/regimens based on End-of-cycle-1 dose limiting toxicity (DLT)</measure>
    <time_frame>after ever DLT within the first cycle, at least 21 days on treatment, every 2 months from first date of enrollment in a particular regimen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the ability to deliver the trastuzumab and vinorelbine therapy</measure>
    <time_frame>After LPLV</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess everolimus, trastuzumab and vinorelbine blood levels in this combination</measure>
    <time_frame>After LPLV</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall tumor response</measure>
    <time_frame>every 9 weeks/minus 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>RAD001 Daily Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg or 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD001 Weekly Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus (RAD001)</intervention_name>
    <arm_group_label>RAD001 Daily Schedule</arm_group_label>
    <arm_group_label>RAD001 Weekly Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female or male patients ≥18 years with WHO performance status ≤ 1

          -  HER-2 overexpressing metastatic breast cancer cells confirmed by histology

          -  Progressive disease on prior trastuzumab alone/or in combination with other anticancer
             agents, or relapsed any time after completion of this therapy

          -  Patients neurologically stable with adequate bone marrow, liver and renal function

        Exclusion criteria:

          -  Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study
             treatment start

          -  Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have
             received these ≤ 4 weeks prior to study treatment start or patients who have received
             lapatinib ≤ 2 weeks prior to study treatment start

          -  Patients who have previously received vinorelbine or mTOR inhibitors

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-overexpressing metastatic breast cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Cancer of the breast</keyword>
  <keyword>Human mammary carcinoma</keyword>
  <keyword>HER-2</keyword>
  <keyword>metastatic</keyword>
  <keyword>everolimus</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

